LILLY: PATENT BOARD CIALIS DECISION OBVIOUSLY WRONG
Eli Lilly & Co. has its day in court today in a bid to overturn two 2016 Patent Trial and Appeal Board decisions holding that patents covering its popular Cialis erectile dysfunction drug are invalid.
The pharmaceutical giant will appear before the Federal Circuit to argue its case. Lilly says PTAB improperly invalidated U.S. Patent Nos. 7,182,958 and 6,821,975 as obvious—by incorrectly assessing the evidence presented as well as devising its own, new obviousness arguments that petitioner Actelion Pharmaceuticals Ltd. hadn’t presented.
Greg Langlois will be at the oral argument.
A federal appeals court has backed the Patent and Trademark Office’s decision to invalidate two patents that gave Eli Lilly and Co. exclusive rights over the active ingredient in its Cialis erectile dysfunction drug.
Daniel Acker/Bloomberg via Getty Images
WHAT TYPES ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.